StonvexLoading…
StonvexStonvexStonvexCore line items from CNM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2026 2026-02-01 | Annual 2025 2025-02-02 | Annual 2024 2024-01-28 | Annual 2023 2023-01-29 |
|---|---|---|---|---|
Revenue | $7.65B | $7.44B | $6.70B | $6.65B |
Operating Income | $722.00M | $719.00M | $740.00M | $775.00M |
Net Income | $441.00M | $411.00M | $371.00M | $366.00M |
EPS (Diluted) | $2.31 | $2.13 | $2.15 | $2.13 |
Total Assets | $6.08B | $5.87B | $5.07B | $4.91B |
Total Liabilities | $4.01B | $4.10B | $3.54B | $2.50B |
Cash & Equivalents | $220.00M | $8.00M | $1.00M | $177.00M |
Free Cash Flow OCF − CapEx | $604.00M | $586.00M | $1.03B | $376.00M |
Shares Outstanding | 197.86M | 201.44M | 227.82M | 246.22M |